<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936429</url>
  </required_header>
  <id_info>
    <org_study_id>HBV-001-C-101</org_study_id>
    <nct_id>NCT00936429</nct_id>
  </id_info>
  <brief_title>Study of HBV-001 D1 in Healthy Adults</brief_title>
  <official_title>Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawaii Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawaii Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and
      tolerability of HBV-001 D1 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and
      tolerability of HBV-001 D1 in healthy adult subjects. This will be an upward titration of two
      dose levels of HBV-001 D1 (10 µg and 50 µg of DEN1-80E) in 16 subjects across two cohorts.
      Participants in each cohort will receive HBV-001 D1 vaccine or placebo on Visits 1, 3 and 5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of the study vaccine formulations in healthy adult subjects by assessing adverse events and laboratory data</measure>
    <time_frame>Assessed at each study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of vaccine dose level on immunogenicity determined by the levels of neutralizing antibodies and cell mediated immune responses</measure>
    <time_frame>Every 2 weeks during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>10 µg DEN1-80E + 3.5 mg Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 µg DEN1-80E + 3.5 mg Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo vaccine at Weeks 0, 4, and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)</intervention_name>
    <description>3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.</description>
    <arm_group_label>10 µg DEN1-80E + 3.5 mg Alhydrogel</arm_group_label>
    <arm_group_label>50 µg DEN1-80E + 3.5 mg Alhydrogel</arm_group_label>
    <other_name>HBV-001 D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for DEN1-80E</intervention_name>
    <description>3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females age 18 to 45.

          -  Body weight ≥ 110 pounds (50 kg).

          -  Satisfactory medical condition established by medical history and physical
             examination.

          -  Females must be of non-child bearing potential (i.e., surgically sterile) or, if of
             child-bearing potential must be abstinent or willing to employ adequate means of
             contraception.

        Exclusion Criteria:

          -  Positive serum test for HIV, Hepatitis B surface antigens (HBsAg) and/or Hepatitis C
             antibodies.

          -  Abuse of drugs or alcohol within 12 months prior to screening.

          -  Use of corticosteroids or immunosuppressive drugs within 30 days of screening (use of
             topical or nasal corticosteroids is allowed).

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition.

          -  Receipt of any vaccination within 30 days prior to screening.

          -  Receipt of blood products within 6 months of screening.

          -  Previous flavivirus vaccination (e.g., Japanese encephalitis or yellow fever) or
             flavivirus vaccination planned during the study period.

          -  History of flavivirus infection.

          -  No easy access to a fixed or mobile telephone.

          -  History of residing in a country endemic for dengue, Japanese encephalitis virus, or
             Yellow Fever virus for a period of &gt; 1 year.

          -  Donation of ≥ 450 mL of blood within the previous 12 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth-Ann Coller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hawaii Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>February 3, 2011</last_update_submitted>
  <last_update_submitted_qc>February 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michele Yelmene</name_title>
    <organization>Hawaii Biotech, Inc</organization>
  </responsible_party>
  <keyword>Dengue fever</keyword>
  <keyword>Dengue hemorrhagic fever</keyword>
  <keyword>Dengue shock syndrome</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Hawaii Biotech</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

